Location
Age
Area of Focus
Website(s)
Social
XAbout Michelle's Work
Michelle Monje is a neuroscientist and neuro-oncologist advancing our understanding of postnatal brain development and translating her findings into promising therapies for pediatric brain tumors. As both a practicing physician and research scientist, Monje brings a unique perspective to her study of the interplay of neuron and glial (support) cells in healthy and diseased states. The potential for her research to translate to clinical treatments for pediatric cancer patients guides many of her projects.
In early work, Monje and her students provided evidence that neuronal activity drives key aspects of brain development. In particular, they found it induces the proliferation of oligodendrocyte precursor cells (a type of glial cell) and increases myelination (the process of protecting and enhancing connections between neurons with an insulating sheathing). Based on this evidence in healthy brain development, Monje hypothesized that neuronal activity may also be driving brain tumor, or glioma, growth, specifically the growth of a lethal childhood brain cancer called diffuse intrinsic pontine glioma (DIPG). She recently made the groundbreaking discovery that glioma cells (including DIPG cells) form electrophysiologically functional synapses with neurons and that these connections produce a positive feedback mechanism that drives tumor development. Monje and colleagues also demonstrated that growth factors released during brain activity, particularly the synaptic protein neuroligin-3, promote the growth of high-grade (fast-growing) gliomas. Monje plays an active role in bringing her findings into clinical settings. She showed that blocking neuroligin-3 secretion in the tumor microenvironment dramatically slows the growth of fast-growing and aggressive tumors (including glioblastoma and DIPG) in mice. In collaboration with other labs, she identified a molecule on the surface of gliomas to target with CAR T-cell therapy (a type of immunotherapy), resulting in the virtual elimination of the tumors in mice. She is currently leading clinical trials for these and other treatment methods.
Monje’s research includes the negative effects chemotherapy has on the developing brain, such as learning and social disabilities that can develop and persist for months or years. Often referred to as “chemobrain,” symptoms include memory lapses, slowed thinking, and mental fog. In a recent study, Monje and colleagues showed that chemotherapy depletes the oligodendrocyte cells required to make myelin and over-activates the microglia (immune cells). Her lab demonstrated that selective depletion of the microglia reversed many of the cognitive symptoms of “chemobrain.” A compassionate physician committed to patient outcomes and a high-impact researcher, Monje is opening new pathways for the study of cancer pathogenesis with the potential to transform treatment of brain cancers.
Biography
Michelle Monje received a BA (1998) from Vassar College and an MD and PhD (2004) from Stanford University. She completed her residency at Harvard Medical School in the Brigham and Women’s Hospital and Massachusetts General Hospital before returning to Stanford for clinical and postdoctoral fellowships. In 2011, Monje joined the faculty at Stanford, where she now serves as an associate professor in the Department of Neurology and Neurological Sciences. In 2021, she was selected as a Howard Hughes Medical Institute Investigator. Her papers have been published in Nature, Science, Cell, Neuron, and Molecular Cell, among other scientific journals.
Published on September 28, 2021
